Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma

• Published in: Cell death & disease Vol. 11; no. 10; p. 925
• Main Authors: Hu, Qinchao, Peng, Jianmin, Jiang, Laibo, Li, Wuguo, Su, Qiao, Zhang, Jiayu, Li, Huan, Song, Ming, Cheng, Bin, Xia, Juan, Wu, Tong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.10.2020; Springer Nature B.V
• Subjects: 13/1; 13/2; 13/21; 13/31; 13/51; 14/19; 38/79; 45/77; 45/90; 631/67/1536; 64/60; 692/699/67/1059; 692/699/67/1536; 96/100; Animals; Antibodies; Antidiabetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antitumor activity; Biochemistry; Biomedical and Life Sciences; Cancer; Cell Biology; Cell Culture; Cell cycle; Cyclin-dependent kinase 4; Cyclin-Dependent Kinase 4 - metabolism; Cyclin-Dependent Kinase 6 - metabolism; Head & neck cancer; Humans; Immunology; Interleukin 6; Investigations; Life Sciences; Medical prognosis; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Mice; Mice, Nude; Patients; Phenotypes; Senescence; Solid tumors; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - drug therapy; Stat3 protein; Survival analysis; TOR protein; Tumorigenesis; Xenograft Model Antitumor Assays; Xenografts; β-Galactosidase

CDK4/6 inhibitors show promising antitumor activity in a variety of solid tumors; however, their role in head and neck squamous cell carcinoma (HNSCC) requires further investigation. The senescence-associated secretory phenotype (SASP) induced by CDK4/6 inhibitors has dual effects on cancer treatmen...